Walleye Capital LLC Purchases New Holdings in Innoviva, Inc. (NASDAQ:INVA)

Walleye Capital LLC acquired a new position in Innoviva, Inc. (NASDAQ:INVA) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,066 shares of the biotechnology company’s stock, valued at approximately $214,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Martingale Asset Management L P boosted its stake in Innoviva by 0.7% during the third quarter. Martingale Asset Management L P now owns 77,842 shares of the biotechnology company’s stock worth $1,503,000 after buying an additional 550 shares in the last quarter. US Bancorp DE boosted its position in shares of Innoviva by 24.5% during the 3rd quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 566 shares in the last quarter. GAMMA Investing LLC increased its stake in Innoviva by 18.5% in the third quarter. GAMMA Investing LLC now owns 4,119 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 643 shares during the period. FMR LLC raised its position in Innoviva by 8.2% in the third quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 771 shares in the last quarter. Finally, SummerHaven Investment Management LLC lifted its stake in Innoviva by 1.7% during the second quarter. SummerHaven Investment Management LLC now owns 59,853 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 980 shares during the period. 99.12% of the stock is currently owned by institutional investors.

Innoviva Stock Down 0.8 %

NASDAQ INVA opened at $18.85 on Thursday. Innoviva, Inc. has a 1-year low of $14.32 and a 1-year high of $21.28. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of 27.32 and a beta of 0.53. The stock’s 50 day moving average is $19.52 and its two-hundred day moving average is $18.39. The company has a current ratio of 1.79, a quick ratio of 1.64 and a debt-to-equity ratio of 0.38.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.25). Innoviva had a net margin of 18.31% and a return on equity of 20.84%. The company had revenue of $89.51 million during the quarter. Equities analysts forecast that Innoviva, Inc. will post 0.33 earnings per share for the current fiscal year.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.